Skip to main content
Sunshine Biopharma Inc. logo

Sunshine Biopharma Inc. — Investor Relations & Filings

Ticker · SBFM ISIN · US8677817004 LEI · 5299005Y64EHRQDQ2Q25 US Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2020-07-13 Director's Dealing
Country US United States of America
Listing US SBFM

About Sunshine Biopharma Inc.

https://www.sunshinebiopharma.com/

Sunshine Biopharma Inc. is a pharmaceutical company engaged in the research, development, and commercialization of life-saving medicines. The company's primary focus is on various therapeutic areas, with a significant emphasis on oncology and antiviral treatments.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2020-07-13 English
PRIMARY DOCUMENT
Director's Dealing
2020-07-10 English
PRIMARY DOCUMENT
Director's Dealing
2020-06-25 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 17, 2020. It reports the issuance of Series B Preferred Stock to the CEO, an amendment to the Articles of Incorporation regarding preferred shares, and includes an exhibit of the amendment. The content focuses on corporate actions related to equity securities and amendments to corporate charter documents. It does not contain financial statements or detailed financial performance data, nor is it an earnings release or annual/interim report. It is not a proxy solicitation or voting results announcement. The primary subject is a capital structure change and corporate governance amendment. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive information about capital changes, not merely an announcement of a report, so it is not RPA or RNS. Confidence is high due to clear identification of equity issuance and amendment to articles of incorporation.
2020-06-24 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 22, 2020. It reports the filing of a new patent application related to a treatment for Coronavirus infections. The document includes a press release as an exhibit and does not contain financial statements or detailed financial data. It is a regulatory announcement about a corporate event (patent filing) rather than a financial report or earnings release. The document length is 3265 characters, which is relatively short and consistent with a regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2020-06-03 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2020
2020-05-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.